SG11201404147YA - Computationally optimized broadly reactive antigens for human and avian h5n1 influenza - Google Patents
Computationally optimized broadly reactive antigens for human and avian h5n1 influenzaInfo
- Publication number
- SG11201404147YA SG11201404147YA SG11201404147YA SG11201404147YA SG11201404147YA SG 11201404147Y A SG11201404147Y A SG 11201404147YA SG 11201404147Y A SG11201404147Y A SG 11201404147YA SG 11201404147Y A SG11201404147Y A SG 11201404147YA SG 11201404147Y A SG11201404147Y A SG 11201404147YA
- Authority
- SG
- Singapore
- Prior art keywords
- avian
- influenza
- human
- reactive antigens
- broadly reactive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261597998P | 2012-02-13 | 2012-02-13 | |
PCT/US2013/025284 WO2013122827A1 (en) | 2012-02-13 | 2013-02-08 | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201404147YA true SG11201404147YA (en) | 2014-10-30 |
Family
ID=48984611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201404147YA SG11201404147YA (en) | 2012-02-13 | 2013-02-08 | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
Country Status (12)
Country | Link |
---|---|
US (3) | US9566327B2 (en) |
EP (2) | EP2814837B1 (en) |
JP (1) | JP6175452B2 (en) |
CN (2) | CN107188934A (en) |
AU (2) | AU2013221877B2 (en) |
CA (1) | CA2863949C (en) |
HK (1) | HK1203523A1 (en) |
IN (1) | IN2014DN05695A (en) |
MX (1) | MX359071B (en) |
MY (1) | MY180109A (en) |
SG (1) | SG11201404147YA (en) |
WO (1) | WO2013122827A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130028933A1 (en) * | 2009-12-28 | 2013-01-31 | Ligocyte Pharmaceuticals, Inc. | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
AU2011302360B2 (en) * | 2010-09-14 | 2015-01-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
EP3199545B1 (en) | 2011-06-20 | 2019-10-30 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
EP2814837B1 (en) * | 2012-02-13 | 2017-11-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
RU2639551C2 (en) | 2012-03-30 | 2017-12-21 | Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Computer-optimized antigens with wide reactivity spectrum for influenza viruses of h5n1 and h1n1 |
KR20150089005A (en) | 2012-11-27 | 2015-08-04 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Computationally optimized broadly reactive antigens for H1N1 influenza |
JP6525214B2 (en) * | 2014-06-03 | 2019-06-05 | 国立研究開発法人農業・食品産業技術総合研究機構 | Antibody or antibody fragment containing the variable region thereof, antigenic polypeptide, and use thereof |
CA2970163A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
EP3307761A4 (en) | 2015-06-09 | 2019-01-16 | Sanofi Pasteur Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
AU2017275663B2 (en) | 2016-06-03 | 2021-12-09 | Sanofi Pasteur Inc. | Modification of engineered influenza hemagglutinin polypeptides |
KR20210088655A (en) * | 2018-11-06 | 2021-07-14 | 베링거잉겔하임베트메디카게엠베하 | Immunogenic composition against avian influenza virus H5 subtype |
WO2020172365A1 (en) * | 2019-02-21 | 2020-08-27 | University Of Georgia Research Foundation | Broadly reactive immunogens of h5 influenza virus, compositions and methods of use thereof |
GB202004825D0 (en) * | 2020-04-01 | 2020-05-13 | Diosynvax Ltd | Influenza vaccines |
AU2022360009A1 (en) * | 2021-10-06 | 2024-05-23 | Diosynvax Ltd | Influenza vaccines |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
JP3468773B2 (en) | 1994-07-15 | 2003-11-17 | ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Immunomodulatory oligonucleotide |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
AU1194802A (en) | 2000-03-02 | 2001-12-11 | Univ Emory | DNA expression vectors and methods of use |
US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
EP1851238A4 (en) | 2005-02-24 | 2008-12-31 | Univ Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
CN1298845C (en) | 2005-09-02 | 2007-02-07 | 中国农业科学院哈尔滨兽医研究所 | Recombinant Newcastle disease LaSota low virulent vaccine strain expressing bird flu virus H5 subtype HA protein |
EP1969510A2 (en) | 2005-12-19 | 2008-09-17 | Novartis Vaccines and Diagnostics S.r.l. | Methods of clustering gene and protein sequences |
US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
WO2007130327A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Influenza virus-like particle (vlp) compositions |
CA2660128A1 (en) | 2006-08-14 | 2008-02-21 | Massachusetts Institute Of Technology | Glycan data mining system |
US8980281B2 (en) | 2006-09-05 | 2015-03-17 | Academia Sinica | High-yield transgenic mammalian expression system for generating virus-like particles |
KR101485197B1 (en) | 2006-09-07 | 2015-01-23 | 크루셀 홀란드 비.브이. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
AU2008331673B2 (en) | 2007-11-12 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
WO2010036970A2 (en) | 2008-09-25 | 2010-04-01 | Fraunhofer Usa, Inc. | Influenza vaccines, antigens, compositions, and methods |
WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
DK2414386T3 (en) | 2009-04-03 | 2016-02-22 | Merial Ltd | Birds of vaccines with newcastle disease virus vectors |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
AU2011302360B2 (en) | 2010-09-14 | 2015-01-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
EP3199545B1 (en) | 2011-06-20 | 2019-10-30 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
AU2013217166B2 (en) | 2012-02-07 | 2017-04-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses |
EP2814837B1 (en) * | 2012-02-13 | 2017-11-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
-
2013
- 2013-02-08 EP EP13749680.8A patent/EP2814837B1/en active Active
- 2013-02-08 SG SG11201404147YA patent/SG11201404147YA/en unknown
- 2013-02-08 US US14/377,633 patent/US9566327B2/en active Active
- 2013-02-08 CN CN201710352437.5A patent/CN107188934A/en active Pending
- 2013-02-08 JP JP2014556708A patent/JP6175452B2/en active Active
- 2013-02-08 WO PCT/US2013/025284 patent/WO2013122827A1/en active Application Filing
- 2013-02-08 EP EP17203380.5A patent/EP3305806B1/en active Active
- 2013-02-08 IN IN5695DEN2014 patent/IN2014DN05695A/en unknown
- 2013-02-08 CA CA2863949A patent/CA2863949C/en active Active
- 2013-02-08 AU AU2013221877A patent/AU2013221877B2/en active Active
- 2013-02-08 MX MX2014008949A patent/MX359071B/en active IP Right Grant
- 2013-02-08 MY MYPI2014002331A patent/MY180109A/en unknown
- 2013-02-08 CN CN201380009263.2A patent/CN104144941B/en active Active
-
2015
- 2015-04-24 HK HK15104017.4A patent/HK1203523A1/en unknown
-
2016
- 2016-12-27 US US15/391,554 patent/US10179805B2/en active Active
-
2018
- 2018-02-09 AU AU2018200962A patent/AU2018200962B2/en active Active
- 2018-12-06 US US16/211,720 patent/US10865228B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10179805B2 (en) | 2019-01-15 |
CN104144941B (en) | 2017-06-09 |
US10865228B2 (en) | 2020-12-15 |
IN2014DN05695A (en) | 2015-05-15 |
US20190092820A1 (en) | 2019-03-28 |
AU2018200962A8 (en) | 2018-03-15 |
CN107188934A (en) | 2017-09-22 |
CN104144941A (en) | 2014-11-12 |
MX359071B (en) | 2018-09-13 |
AU2018200962A1 (en) | 2018-03-01 |
AU2013221877B2 (en) | 2017-11-09 |
JP2015512871A (en) | 2015-04-30 |
AU2013221877A1 (en) | 2014-08-28 |
US20170107262A1 (en) | 2017-04-20 |
CA2863949C (en) | 2021-06-29 |
EP3305806B1 (en) | 2020-08-26 |
US9566327B2 (en) | 2017-02-14 |
MY180109A (en) | 2020-11-23 |
HK1203523A1 (en) | 2015-10-30 |
MX2014008949A (en) | 2014-10-24 |
EP2814837A4 (en) | 2015-07-22 |
AU2018200962B2 (en) | 2019-06-06 |
US20160022805A1 (en) | 2016-01-28 |
EP2814837B1 (en) | 2017-11-29 |
EP3305806A1 (en) | 2018-04-11 |
JP6175452B2 (en) | 2017-08-02 |
EP2814837A1 (en) | 2014-12-24 |
CA2863949A1 (en) | 2013-08-22 |
WO2013122827A1 (en) | 2013-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203523A1 (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza h5n1 | |
IL276182A (en) | Human immunodeficiency virus neutralizing antibodies and methods of use thereof | |
IL262123A (en) | Influenza virus vaccines and uses thereof | |
HK1245128A1 (en) | Antigens and vaccines directed against human enteroviruses | |
HK1203522A1 (en) | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses h5n1 h1n1 | |
HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
HK1199211A1 (en) | Influenza virus vaccines and uses thereof | |
EP2721158A4 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
EP2814841A4 (en) | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same | |
HK1203524A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses h3n2h2n2 b | |
EP2616545A4 (en) | Computationally optimized broadly reactive antigens for influenza | |
HK1212708A1 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza h1n1 | |
EP3233117A4 (en) | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
HK1209455A1 (en) | Pluripotent germ layer origin antigen presenting cancer vaccine | |
EP2701735A4 (en) | Liquid vaccine preparations | |
HK1201283A1 (en) | Influenza c virus and vaccine | |
EP2739306A4 (en) | Optimized antigens of pneumocystis and use thereof | |
EP2776462A4 (en) | Indolealkylamino-withasteroid conjugates and method of use | |
GB201108166D0 (en) | Essq Zamayl Sithole - Coat of arms: and Zamayl Sithole coat of arms |